Be the first person to write a business review for LGC (Holdings) Limited

Life Sciences Research stands ready to test everything that humans, animals, and the environment eat, use, and are exposed to. The contract research organization (CRO) performs safety and efficacy tests on pharmaceutical and chemical compounds used in products being developed by drug, agricultural, industrial, and veterinary companies. Life Sciences Research and its subsidiaries provide both large and start-up drugmaker clients worldwide with toxicology, metabolism, and stability studies for preclinical candidates that are applying for product approval. The company was taken private in 2009 after being acquired by Lion Holdings.

Life Technologies Corporation operates as a global biotechnology tools company focused on improving the human condition. Its systems, consumables, and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that better the quality of life. Life Technologies' customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. The company delivers a range of products and services, including systems, instruments, reagents, and custom services. Its portfolio of products includes technologies for capillary electrophoresis based sequencing, next generation sequencing, mass spectrometry, sample preparation, cell culture, RNA interference analysis, functional genomics research, proteomics, and cell biology applications, as well as clinical diagnostic applications and water testing analysis. The company has a presence in approximately 100 countries, and possesses a growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems, Inc. It has a strategic alliance agreement with Applied Biosystems designed to accelerate research into complex diseases and medical conditions; and strategic scientific research collaboration with The University of Queensland's Institute for Molecular Bioscience to study pancreatic and ovarian cancer in Australia. The company is based in Carlsbad, California.

Lifecore Biomedical hopes to help bodies plump up, smooth out, and keep moving. Lifecore's hyaluronan division makes products using hyaluronan, a natural lubricating compound found in animal and human connective tissues. The products are used in cataract surgeries, bone grafting, pain treatments for osteoarthritis, and veterinary orthopedics. Hyaluronan is also being tapped for use in cosmetic procedures as a dermal filler (to smooth out wrinkles). Lifecore has supply agreements with Alcon to use its hyaluronan solution in cataract surgery products. In 2008 the firm was taken private by Warburg Pincus.

LifeSpan BioSciences likes the way genes express themselves. The firm helps drugmakers develop new product candidates faster by finding proteins and RNA in human tissue samples to identify gene expression associated with disease. It licenses access to its databases of gene expressions and protein localizations to drug developers. Also available are target validation and tissue pathology services. LifeSpan's clients include pharmaceutical companies in Asia, Europe, and North America.

Ligand Pharmaceuticals Incorporated company was founded in 1987. Ligand Pharmaceuticals Incorporated (Ligand) is a biotechnology company that focuses on drug discovery and early-stage development of pharmaceuticals that address critical unmet medical needs or that are more effective and/or safer than existing therapies, more convenient to administer and are cost effective. The Company has research and development collaborations for its product candidates with numerous pharmaceutical companies. These collaborations include ongoing clinical programs at Bristol-Myers Squibb (BMS), GlaxoSmithKline (GSK), Pfizer, Schering-Plough, Wyeth, Cephalon and Celgene. It receives royalty revenues from King Pharmaceuticals (King), and GSK. In February 2007, it completed the sale of its AVINZA product line to King. Through October 2008, it received a 15% royalty on AVINZA net sales. On December 23, 2008, it acquired all of the outstanding common shares of Pharmacopeia, Inc. In December 2009, Ligand Pharmaceuticals Incorporated acquired Neurogen Corporation.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.